{"name":"JCR Pharmaceuticals","slug":"jcr","ticker":"4552.T","exchange":"TSE","domain":"jcrpharm.co.jp","description":"JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene","hq":"Ashiya, Hyogo, Japan","founded":1997,"employees":"987","ceo":"Shin Ashida","sector":"Rare Disease / CNS Enzyme Replacement","stockPrice":536,"stockChange":-27,"stockChangePercent":-4.8,"marketCap":"$413M","metrics":{"revenue":237377194.78257254,"revenueGrowth":0,"grossMargin":70.5,"rdSpend":0,"netIncome":-15420508.14923817,"cash":98902418.89628549,"dividendYield":3.55,"peRatio":14.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Laronidase patent cliff ($100.0M at risk)","drug":"Laronidase","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Vimizim patent cliff ($50.0M at risk)","drug":"Vimizim","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"JR-141","genericName":"JR-141","slug":"jr-141","indication":"Metachromatic leukodystrophy (MLD)","status":"phase_3"},{"name":"JR-141 or Idursulfase","genericName":"JR-141 or Idursulfase","slug":"jr-141-or-idursulfase","indication":"Hunter syndrome (mucopolysaccharidosis II, MPS II) with central nervous system involvement","status":"phase_3"}]}],"pipeline":[{"name":"JR-141","genericName":"JR-141","slug":"jr-141","phase":"phase_3","mechanism":"JR-141 is a recombinant human arylsulfatase A enzyme designed to cross the blood-brain barrier and replace deficient enzyme activity in lysosomal storage disorders.","indications":["Metachromatic leukodystrophy (MLD)"],"catalyst":""},{"name":"JR-141 or Idursulfase","genericName":"JR-141 or Idursulfase","slug":"jr-141-or-idursulfase","phase":"phase_3","mechanism":"JR-141 is a recombinant idursulfase enzyme that replaces deficient iduronate-2-sulfatase to break down glycosaminoglycans in Hunter syndrome.","indications":["Hunter syndrome (mucopolysaccharidosis II, MPS II) with central nervous system involvement"],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"JCR Pharmaceuticals Receives FDA Approval for Laronidase","summary":"JCR Pharmaceuticals announced that the FDA has approved its application for laronidase, a treatment for mucopolysaccharidosis I.","drugName":"Laronidase","sentiment":"positive"},{"date":"2023-08-10","type":"earnings","headline":"JCR Pharmaceuticals Reports Strong Q2 Earnings","summary":"JCR Pharmaceuticals reported strong Q2 earnings, driven by growth in its rare disease business.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPd1pub1FOZlFjYXY4cTc0MUhHWUhFMlloNFd6THVrT2FBTXZNa2Q3YnBsWUpJWXhGZ3BMUFUtNkRkWUt4U1BFTFUzM3RBeFVTMU9yOWd6Nl95THluRFd5NXJqcm5MUURIMGtoZXFHZGprYUE2dkFXcEVyMnhJTFVZMFFZejBTcExmODUtek5TX0NhVEtNSVcza3U1MA?oc=5","date":"2025-10-01","type":"pipeline","source":"Yahoo Finance","summary":"JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets - Yahoo Finance","headline":"JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNeEtUZUFRTXhXVkh6NjhFYk40OGNBemliQlc4Z1JZQXVDNFhsaG1IeXJPUGNNX1JGREVvUmcyQ2dkZTM3UlViYWJ2NUl0RHFpaFg3QndiOXZ1c1lPY2ItYUhQMnVIS1ZQVWZDcHZMVUp2UDhiRVEtc0YxdTByXy0wNll0VHBhN0xmQl9oYUpYSWwzSnpTWDY0ZFZiMEdDT2RxOXE2UWFWS3dkWElMT2FPaFJVVV8yUzZ3SkUzMW1XTXFpQ2Z2QVdCTXpOZmhrZlJ5bi1KYUZR?oc=5","date":"2025-07-16","type":"pipeline","source":"Business Wire","summary":"JCR Pharmaceuticals Selected for Japan’s Regenerative Medicine CDMO Subsidy Program - Business Wire","headline":"JCR Pharmaceuticals Selected for Japan’s Regenerative Medicine CDMO Subsidy Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxQTDkteFRWak9LUEZUZy1oZ2hoc1Z0Q1YyUlAtVHBkZHBzbXV0WE9tNExwUEs5SHI5UF9VbEkwNVVRQVVCRHBMSHZEMXExZUpQTDcwYjBuN3Y2OGdHUE93SFZsTVhaMjYtUUJNbEh3RVJiRHZqWHpYSGhfTlluZk9fNHQ5UG1iRlMwWXJodlpsSkxOeEI4ZTI2TjFTYTFrdm55Z0FSMmpMY19VRVJGSFd5NGk3a0NTVGZzUi01ejh0c0paUHBJMC1DZ0pJaUhsdjJ5cDlBRWdjTUxlMllvUXNISHAwUWZZbklJRVI2R09qY25sdVhiUkdrc2EyWVRqQzZIUm1sX2RZTVFaNUpCOXc?oc=5","date":"2025-07-08","type":"deal","source":"BioSpace","summary":"JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines - BioSpace","headline":"JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxNakY2MEs1a0w3a2VRamZhajZPZFpBWEZ3TDA4SWo4eG91c1NlZ3gzUFpVN2hyUGZNakRDSU1lVmc5QjFCbHNwandzV2JsbVJodmVjYWhwNE9FQUc5b2dGWU5yTVltVDhEaVBwNjdDbF9OTzZGdWhVODFMUEpKM1JUeHpIdXV2Y3gxZjlHemhNckg3NnNxSXg5dDNvc0pRamN2S1NxMUtzdVJGLUxGMHJtdE1XM1RDdlU2NGdfbE1GakZxMjdqVmc5Tm9QXzgtRFpsVzNSMG1xNjRhNndmNWdIYk55ek5QdXVGSTNHZ19SN0RTUXptUGl2bFFrdVJ3c2xt?oc=5","date":"2021-03-23","type":"pipeline","source":"Business Wire","summary":"(Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japan - Business Wire","headline":"(Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5wc2YzaVUzN1BoaFhNdUJrd1FkVktyZ1hjOVFwYzNUTkZRTkIyTUhUMEdxZVZCeEw5aUpBUjN4UEE1dG53V1pEMjd6VkNXeEFaaFRrTg?oc=5","date":"2020-11-07","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Takara Bio Inc. (4974.T) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Takara Bio Inc. (4974.T) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Vimizim","drugSlug":"elosulfase-alfa","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":50000000},{"drugName":"Laronidase","drugSlug":"alpha-l-iduronidase","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Shire","BioMarin","Sanofi Genzyme"],"therapeuticFocus":["Rare Diseases","CNS Enzyme Replacement"],"financials":{"source":"yahoo_finance","revenue":209096774.1408,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":209096774.1408},{"period":"2024-03-31","value":271050671.3894},{"period":"2023-03-31","value":217132635.2902},{"period":"2022-03-31","value":322964484.0548}],"grossProfit":137437883.2932,"grossProfitHistory":[{"period":"2025-03-31","value":137437883.2932},{"period":"2024-03-31","value":197583553.7214},{"period":"2023-03-31","value":160944831.95839998},{"period":"2022-03-31","value":256818788.26799998}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":-42050757.281399995,"operatingIncomeHistory":[{"period":"2025-03-31","value":-42050757.281399995},{"period":"2024-03-31","value":47620854.5848},{"period":"2023-03-31","value":31460617.6864},{"period":"2022-03-31","value":126032144.88759999}],"netIncome":-30088641.3926,"netIncomeHistory":[{"period":"2025-03-31","value":-30088641.3926},{"period":"2024-03-31","value":34817849.9998},{"period":"2023-03-31","value":23848362.1208},{"period":"2022-03-31","value":91720092.59979999}],"eps":43.92,"epsHistory":[{"period":"2024-03-31","value":43.92},{"period":"2023-03-31","value":30.22},{"period":"2022-03-31","value":116.8}],"cash":83431332.5944,"cashHistory":[{"period":"2025-03-31","value":83431332.5944},{"period":"2024-03-31","value":118584273.5784},{"period":"2023-03-31","value":83949775.2492},{"period":"2022-03-31","value":194308513.5362}],"totalAssets":662942738.647,"totalLiabilities":363036307.788,"totalDebt":240917772.697,"equity":297409054.656,"operatingCashflow":-34685078.1004,"operatingCashflowHistory":[{"period":"2025-03-31","value":-34685078.1004},{"period":"2024-03-31","value":58874853.6768},{"period":"2023-03-31","value":-34773592.699999996},{"period":"2022-03-31","value":58729436.8346}],"capex":-62516597.2032,"capexHistory":[{"period":"2025-03-31","value":-62516597.2032},{"period":"2024-03-31","value":-9648091.3564},{"period":"2023-03-31","value":-54120355.184},{"period":"2022-03-31","value":-72120431.2598}],"freeCashflow":-97201675.3036,"dividendsPaid":-15837790.856999999,"buybacks":null,"employees":987,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-06-30","revenue":null,"epsBasic":-4.48,"netIncome":null,"rdExpense":null,"epsDiluted":-4.48,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":536,"previousClose":563,"fiftyTwoWeekHigh":824,"fiftyTwoWeekLow":448,"fiftyTwoWeekRange":"448.0 - 824.0","fiftyDayAverage":581.02,"twoHundredDayAverage":640.89,"beta":0.17,"enterpriseValue":649815493.4503179,"forwardPE":14.6,"priceToBook":1.41,"priceToSales":1.74,"enterpriseToRevenue":2.74,"enterpriseToEbitda":-48.43,"pegRatio":0,"ebitda":-13417864.827490456,"ebitdaMargin":-5.7,"freeCashflow":0,"operatingCashflow":0,"totalDebt":332637876.62666875,"debtToEquity":112.5,"currentRatio":1.16,"returnOnAssets":-3.2,"returnOnEquity":-4.9,"analystRating":"2.7 - Hold","recommendationKey":"hold","numberOfAnalysts":6,"targetMeanPrice":716.67,"targetHighPrice":900,"targetLowPrice":550,"dividendRate":20,"payoutRatio":0.61,"fiveYearAvgDividendYield":2.04,"exDividendDate":1790640000,"insiderHeldPercent":41.5,"institutionHeldPercent":11.8,"sharesOutstanding":121992906,"floatShares":71441339,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-18.86,"epsForward":36.62,"revenuePerShare":307.86,"bookValue":379.73,"officers":[{"age":57,"name":"Toru  Ashida","title":"Chairman of the Board"},{"age":47,"name":"Mr. Hiroyuki  Sonoda Ph.D.","title":"President, Chief Scientific Officer & Representative Director"},{"age":82,"name":"Mr. Shin  Ashida","title":"Founder & Director"},{"age":null,"name":"Yoshihiro  Ota","title":"Director of Accounting Department & Corporate Strategy Department (Finance)"},{"age":null,"name":"Mr. Yutaka  Honda","title":"Senior Managing Executive Officer, Exec Director of Administration Div. & Head of Exec Office"},{"age":null,"name":"Mr. Hiroyuki  Fukuya","title":"Exec Off, Dir of Legal & Compliance, Internal Control Dept and Chief Legal & Compliance Off"},{"age":null,"name":"Takafumi  Shimizu","title":"Director of Marketing Dept. & Sales Division"},{"age":null,"name":"Shinji  Okamoto","title":"Director of Human Resources Department & Administration Division"}],"industry":"Drug Manufacturers - General","irWebsite":"","website":"https://www.jcrpharm.co.jp","phone":"81 7 9732 8591"}}